Comparing the current results to its competitors, Structure Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 5.71 %, recorded in the same quarter.
December 17, 2024
The effective management of obesity remains a daunting challenge in pharmacotherapy, amidst rising prevalence rates and associated comorbidities. Structure Therapeutics Inc. has recently advanced its developmental pipeline with the announcement of its lead oral small molecule amylin receptor agonist, ACCG-2671, targeting the treatment of obesity. This article elucidates the preclinical findings that underscore the therapeutic potential of ACCG-2671, along with a financial analysis of the company s Leverage Ratio, providing a comprehensive view of its position within the pharmaceutical landscape. ACCG-2671: A Novel Approach to Obesity Treatment ACCG-2671 has emerged from extensive preclinical studies demonstr...
June 3, 2024
Obesity has become a global epidemic, with significant health and economic burdens. Considering the limited efficacy and potential safety concerns associated with existing anti-obesity medications, the development of novel therapeutic agents is of utmost importance. In this article, we present the positive topline data from the Phase 2a clinical trial evaluating the efficacy of GSBR-1290, an oral non-peptide small molecule GLP-1 receptor agonist, in promoting weight loss in obese individuals. Additionally, we discuss the results of a capsule to tablet pharmacokinetic (PK) study that further supports the potential of GSBR-1290 as a promising therapeutic optionPhase 2a Obesity Study Results:Structure Therapeut...
Structure Therapeutics, a leading biopharmaceutical company, has recently released an extensive update on their GSBR-1290 program, including encouraging proof-of-concept data from a Phase 2a clinical study. This article aims to delve into the study s findings and shed light on the potential therapeutic benefits of GSBR-1290 in individuals suffering from diabetes and obesity. Clinical Findings: During the 12-week study, GSBR-1290 demonstrated an excellent safety profile, with no treatment-related serious adverse events reported. This crucial finding confirms the drug s overall tolerability and enhances its prospects for further development. Moreover, the discontinuation rate due to adverse e...
Publicly Traded Peers of Structure Therapeutics Inc
Sanofi Share Performance
-4.80%
This Quarter
Sanofi
Profile
Sanofi's business model revolves around the development, production, and distribution of pharmaceutical products. They aim to innovate and provide healthcare solutions across various therapeutic areas to improve patients' lives worldwide. Sanofi collaborates with partners and healthcare professionals to ensure effective delivery of their products and to address evolving patient needs.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
Sources:
Structure Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Structure Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
